Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Perros, S. Cohen-Kaminsky, N. Gambaryan, B. Girerd, N. Raymond, I. Klingelschmitt, A. Huertas, O. Mercier, E. Fadel, G. Simonneau, M. Humbert, P. Dorfmüller, D. Montani (Le Kremlin-Bicêtre, Le Plessis-Robinson, France). Granulysin in pulmonary veno-occlusive disease. Eur Respir J 2013; 42: Suppl. 57, 481

Member's Comments

No comment yet.

Related content which might interest you: Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary hypertension associated with sarcoidosis Source: Eur Respir Mon 2012; 57: 166-181 Year: 2012 Immune signatures in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Characteristics of patients with pulmonary hypertension in end stage renal disease Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 The incidence of chronic thromboembolic pulmonary hypertension in asympthomatic pulmonary embolism patients Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Pulmonary hypertension complicating fibrosing mediastinitis Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Immunity in idiopathic pulmonary arterial hypertension (IPAH), a role for activated DCs? Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension Source: Eur Respir Rev 2009; 18: 177-180 Year: 2009 Risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Smad1 deficiency and female gender contribute to the development of pulmonary hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014